Jolyon Mitchell will present the DDL Award Lecture at DDL 24
“We chose Jolyon,” organizing committee chair Gary Pitcairn said, “due to his extensive experience in OINDP, his contributions to inhalation science and his significant involvement in the area for many years.” Mitchell’s lecture, titled, “Taking the Evaluation of Orally Inhaled Products in the Laboratory to the Next Level: Introducing the Patient Experience into the Picture,” will kick off the conference on the afternoon of December 11.
Four of the six finalists for this year’s Pat Burnell New Investigator Award also come from outside the UK. “We’re very pleased that we offer this opportunity for talented younger investigators to present their research,” says Forbes. In order to encourage participation by student researchers, the student delegate rate for the conference is only £150, and the Aerosol Society offers travel grants for UK and Irish students presenting posters or papers.
The finalists will present their work during a Thursday morning podium session. “We’ve had a high level of submissions for the award, and we have former poster winners now coming back with presentations on the podium. Last year’s winner of the Pat Burnell Award, Martin Rowland, is part of the judging panel this year and will be giving a presentation of his own on Friday morning.” As in past years, Prizes for the Pat Burnell Award and for the best industrial and academic posters will be presented during a drinks reception on the evening of December 12.
In addition to the Pat Burnell Award session, program sessions include:
- Aerosol nano-medicines: friend or foe?
- Role of Pharmacokinetics and Pharmacodynamics in developing inhaled products
- Formulation approaches for new inhaled therapies
- Recent developments in respiratory technology.
A number of the invited papers cover topics suggested by delegates at previous DDL meetings, according to Forbes, including a paper on analysis of nasal products and the session on new inhaled therapies such as treatments for lung cancer, gene therapy for cystic fibrosis, and antibiotics. Other anticipated highlights include a presentation titled “Rationale behind the recent Draft Guidance on Fluticasone Propionate/Salmeterol Xinafoate” by Sau Lee of the US FDA, a review of the year in OINDPs by consultant Steve Nichols, and a talk on the implications of ageing for drug therapies.
Feedback from attendees at this year’s conference, Forbes notes, will be particularly welcome as the organizers begin to plan for the Silver Jubilee (DDL25) conference in 2014.
